Cargando…

SARS CoV- 2 vaccination induces antibodies against cardiolipin

OBJECTIVE: Cases of thrombosis have been reported after administration of SARS-CoV-2 vaccines, with controversial results relating to Oxford-AstraZeneca’s ChAdOx1-S. Despite such cases being rare, they still raised concerns for their involvement in coagulopathies. Anti-cardiolipin (aCL) IgG antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krashias, George, Pafiti, Anna, Deeba, Elie, Christodoulou, Christina, Pantzaris, Marios, Lambrianides, Anastasia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449922/ https://www.ncbi.nlm.nih.gov/pubmed/36071440 http://dx.doi.org/10.1186/s13104-022-06180-3

Ejemplares similares

SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments
por: Lambrianides, Anastasia, et al.
Publicado: (2023)

The expression profile of virus-recognizing toll-like receptors in natural killer cells of Cypriot multiple sclerosis patients
por: Deeba, Elie, et al.
Publicado: (2020)

A Preclinical Investigation on the Role of IgG Antibodies against Coagulant Components in Multiple Sclerosis
por: Hadjiagapiou, Maria S., et al.
Publicado: (2023)

Serum Reactive Antibodies against the N-Methyl-D-Aspartate Receptor NR2 Subunit—Could They Act as Potential Biomarkers?
por: Hadjiagapiou, Maria S., et al.
Publicado: (2023)

Genetic Markers for Thrombophilia and Cardiovascular Disease Associated with Multiple Sclerosis
por: Hadjiagapiou, Maria S., et al.
Publicado: (2022)

Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca
por: Deeba, Elie, et al.
Publicado: (2022)

A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
por: Pafiti, Anna, et al.
Publicado: (2023)

Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
por: Krashias, George, et al.
Publicado: (2021)

SARS-CoV-2 and Anti-Cardiolipin Antibodies
por: Jizzini, Mazen, et al.
Publicado: (2020)

The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin
por: Giles, Ian, et al.
Publicado: (2005)

Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature
por: Lambrianides, Sakis, et al.
Publicado: (2018)

Molecular epidemiology of SARS-CoV-2 in Cyprus
por: Richter, Jan, et al.
Publicado: (2021)

Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
por: Miyakawa, Kei, et al.
Publicado: (2021)

Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2022)

HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities
por: Krashias, George, et al.
Publicado: (2017)

Antibodies against Native and Oxidized Cardiolipin and Phosphatidylserine and Phosphorylcholine in Atherosclerosis Development
por: Frostegård, Anna G., et al.
Publicado: (2014)

Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects
por: Manenti, Alessandro, et al.
Publicado: (2022)

The kinetics of viral load and antibodies to SARS-CoV-2
por: Sun, Jiufeng, et al.
Publicado: (2020)

Cardiolipin Antibody: A Potential Biomarker for Depression
por: Costa, Renzo, et al.
Publicado: (2022)

Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron
por: Adachi, Eisuke, et al.
Publicado: (2022)

Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination
por: Nakagama, Yu, et al.
Publicado: (2023)

In depth analysis of Cyprus-specific mutations of SARS-CoV-2 strains using computational approaches
por: Oulas, Anastasis, et al.
Publicado: (2021)

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
por: Mveang Nzoghe, Amandine, et al.
Publicado: (2021)

Persistence of the neutralizing antibody response after SARS-CoV-2 infection
por: Shim, Sang-Mu, et al.
Publicado: (2022)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
por: Rozen-Zvi, Benaya, et al.
Publicado: (2021)

Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study
por: Lambrianides, Sakis, et al.
Publicado: (2019)

Long-term transition of antibody titers in healthcare workers following the first to fourth doses of mRNA COVID-19 vaccine: Comparison of two automated SARS-CoV-2 immunoassays
por: Taniguchi, Yumi, et al.
Publicado: (2023)

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
por: Saiag, Esther, et al.
Publicado: (2022)

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Alterations in Laboratory Parameters Related to Disease Severity in Vaccinated Patients Against SARS-CoV-2
por: Lagadinou, Maria, et al.
Publicado: (2022)

Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
por: Lo, Angela, et al.
Publicado: (2022)

SARS-CoV-2 vaccine humoral response in adults with Down syndrome
por: Sali, Michela, et al.
Publicado: (2022)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Huh, Jung Eun, et al.
Publicado: (2021)

Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies
por: Vellas, Camille, et al.
Publicado: (2022)

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
por: Favresse, Julien, et al.
Publicado: (2021)

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)

Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination()
por: Pezzati, Laura, et al.
Publicado: (2023)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
por: Markewitz, Robert, et al.
Publicado: (2022)

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
por: Gressens, Simon B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0aapjpl347231rbqpotbc54eeu